Loading...
XNAS
BJDX
Market cap2mUSD
Jul 09, Last price  
1.67USD
1D
0.60%
1Q
-35.27%
IPO
-99.79%
Name

Bluejay Diagnostics Inc

Chart & Performance

D1W1MN
P/E
P/S
EPS
Div Yield, %
Shrs. gr., 5y
56.28%
Rev. gr., 5y
%
Revenues
0k
000249,04000
Net income
-8m
L-22.46%
-757,716-1,125,716-3,729,686-9,227,889-9,953,888-7,717,794
CFO
-8m
L-5.94%
-1,690,118-508,710-4,366,758-7,741,593-8,313,870-7,819,769

Profile

Bluejay Diagnostics, Inc., a diagnostic company, develops and markets patient products for triage, diagnosis, and monitoring of disease progression in the United States. It is developing Symphony platform, a technology platform comprising Symphony Fluorescence Immuno-analyzer that orchestrates blood processing, biomarker isolation, and immunoassay preparation using non-contact centrifugal force; and Symphony Cartridge Library, which includes reagents and components. The company also offers ALLEREYE diagnostic test, a POC device for the diagnosis of allergic conjunctivitis. In addition, it develops biomarkers for detection of other diseases such as hsTNT/I for myocardial injury and NT-proBNP for cardiac heart failure. It has a license and supply agreement with Toray Industries, Inc. for making and distributing the protein detection chips. Bluejay Diagnostics, Inc. was incorporated in 2015 and is headquartered in Acton, Massachusetts.
IPO date
Nov 10, 2021
Employees
16
Domiciled in
US
Incorporated in
US

Valuation

Title
USD in thousands, except ratios and share amounts
FYFYFYFYFYFY
2024‑122023‑122022‑122021‑122020‑122019‑12
Income
Revenues
249
 
Cost of revenue
7,170
11,092
9,567
Unusual Expense (Income)
NOPBT
(7,170)
(11,092)
(9,318)
NOPBT Margin
Operating Taxes
(69)
Tax Rate
NOPAT
(7,170)
(11,092)
(9,249)
Net income
(7,718)
-22.46%
(9,954)
7.87%
(9,228)
147.42%
Dividends
Dividend yield
Proceeds from repurchase of equity
12,069
160
29
BB yield
-1,351.34%
-11.95%
-0.38%
Debt
Debt current
113
163
169
Long-term debt
331
543
817
Deferred revenue
Other long-term liabilities
9
12
16
Net debt
(3,857)
(1,503)
(9,130)
Cash flow
Cash from operating activities
(7,820)
(8,314)
(7,742)
CAPEX
(307)
(704)
(1,199)
Cash from investing activities
(307)
(704)
(1,199)
Cash from financing activities
10,220
1,112
8
FCF
(7,274)
(10,812)
(9,835)
Balance
Cash
4,302
2,209
10,115
Long term investments
Excess cash
4,302
2,209
10,103
Stockholders' equity
(34,669)
(26,951)
(16,995)
Invested Capital
40,629
30,211
29,045
ROIC
ROCE
EV
Common stock shares outstanding
183
137
126
Price
4.87
-50.10%
9.76
-83.94%
60.78
-85.16%
Market cap
893
-33.24%
1,338
-82.54%
7,660
-64.89%
EV
(2,964)
(165)
(1,469)
EBITDA
(6,971)
(10,311)
(9,011)
EV/EBITDA
0.43
0.02
0.16
Interest
823
21
Interest/NOPBT